Wellington Management Group LLP Sells 711,985 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Wellington Management Group LLP decreased its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 10.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,004,598 shares of the company's stock after selling 711,985 shares during the quarter. Wellington Management Group LLP owned approximately 6.60% of Myriad Genetics worth $82,323,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. raised its position in Myriad Genetics by 43.8% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company's stock valued at $132,000 after purchasing an additional 1,471 shares during the last quarter. Blue Trust Inc. raised its position in shares of Myriad Genetics by 14.1% during the fourth quarter. Blue Trust Inc. now owns 14,451 shares of the company's stock worth $198,000 after acquiring an additional 1,788 shares during the last quarter. Swiss National Bank raised its position in shares of Myriad Genetics by 1.0% during the fourth quarter. Swiss National Bank now owns 178,600 shares of the company's stock worth $2,449,000 after acquiring an additional 1,800 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Myriad Genetics by 0.4% during the fourth quarter. Bank of New York Mellon Corp now owns 646,003 shares of the company's stock worth $8,857,000 after acquiring an additional 2,256 shares during the last quarter. Finally, KBC Group NV raised its position in shares of Myriad Genetics by 132.8% during the fourth quarter. KBC Group NV now owns 5,845 shares of the company's stock worth $80,000 after acquiring an additional 3,334 shares during the last quarter. Institutional investors own 99.02% of the company's stock.

Analyst Upgrades and Downgrades

MYGN has been the subject of a number of recent research reports. Craig Hallum initiated coverage on Myriad Genetics in a research report on Wednesday, February 12th. They set a "buy" rating and a $29.00 target price for the company. The Goldman Sachs Group dropped their target price on Myriad Genetics from $29.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Guggenheim cut Myriad Genetics from a "buy" rating to a "neutral" rating in a research note on Wednesday. Raymond James reaffirmed an "outperform" rating and set a $19.00 price objective (down from $27.00) on shares of Myriad Genetics in a research note on Tuesday, February 25th. Finally, UBS Group decreased their price objective on Myriad Genetics from $18.00 to $16.00 and set a "neutral" rating for the company in a research note on Tuesday, February 25th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $20.89.

Myriad Genetics Trading Down 5.9 %

NASDAQ:MYGN traded down $0.50 on Thursday, reaching $7.96. The company's stock had a trading volume of 124,000 shares, compared to its average volume of 894,064. Myriad Genetics, Inc. has a 1-year low of $7.35 and a 1-year high of $29.30. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. The firm has a market cap of $726.36 million, a PE ratio of -6.14 and a beta of 1.87. The business's 50-day moving average price is $10.90 and its two-hundred day moving average price is $15.24.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.12). The firm had revenue of $210.60 million during the quarter, compared to the consensus estimate of $210.35 million. Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. During the same quarter last year, the firm earned ($0.12) earnings per share. Equities research analysts anticipate that Myriad Genetics, Inc. will post -0.3 earnings per share for the current fiscal year.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.